Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 21;8(7):bvae101.
doi: 10.1210/jendso/bvae101. eCollection 2024 May 23.

Clinical and Molecular Characterization of Hyperinsulinism in Kabuki Syndrome

Elizabeth Rosenfeld  1   2 , Lauren M Mitteer  1 , Kara Boodhansingh  1 , Victoria R Sanders  1 , Heather McKnight  1 , Diva D De Leon  1   2
Affiliations

Clinical and Molecular Characterization of Hyperinsulinism in Kabuki Syndrome

Elizabeth Rosenfeld et al. J Endocr Soc. .

Abstract

Context: Kabuki syndrome (KS) is associated with congenital hyperinsulinism (HI).

Objective: To characterize the clinical and molecular features of HI in children with KS.

Design: Retrospective cohort study of children with KS and HI evaluated between 1998 and 2023.

Setting: The Congenital Hyperinsulinism Center of the Children's Hospital of Philadelphia.

Patients: Thirty-three children with KS and HI.

Main outcome measures: HI presentation, treatment, course, and genotype.

Results: Hypoglycemia was recognized on the first day of life in 25 children (76%). Median age at HI diagnosis was 1.8 months (interquartile range [IQR], 0.6-6.1 months). Median age at KS diagnosis was 5 months (IQR, 2-14 months). Diagnosis of HI preceded KS diagnosis in 20 children (61%). Twenty-four children (73%) had a pathogenic variant in KMT2D, 5 children (15%) had a pathogenic variant in KDM6A, and 4 children (12%) had a clinical diagnosis of KS. Diazoxide trial was conducted in 25 children, 92% of whom were responsive. HI treatment was discontinued in 46% of the cohort at median age 2.8 years (IQR, 1.3-5.7 years).

Conclusion: Hypoglycemia was recognized at birth in most children with KS and HI, but HI diagnosis was often delayed. HI was effectively managed with diazoxide in most children. In contrast to prior reports, the frequency of variants in KMT2D and KDM6A were similar to their overall prevalence in individuals with KS. Children diagnosed with KS should undergo evaluation for HI, and, because KS features may not be recognized in infancy, KMT2D and KDM6A should be included in the genetic evaluation of HI.

Keywords: KDM6A; KMT2D; diazoxide; hypoglycemia; insulin.

PubMed Disclaimer

References

    1. Niikawa N, Kuroki Y, Kajii T, et al. Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients. Am J Med Genet. 1988;31(3):565‐589. - PubMed
    1. Kuroki Y, Suzuki Y, Chyo H, Hata A, Matsui I. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr. 1981;99(4):570‐573. - PubMed
    1. Niikawa N, Matsuura N, Fukushima Y, Ohsawa T, Kajii T. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr. 1981;99(4):565‐569. - PubMed
    1. Adam MP, Banka S, Bjornsson HT, et al. Kabuki syndrome: international consensus diagnostic criteria. J Med Genet. 2019;56(2):89‐95. - PubMed
    1. Armstrong L, Abd El Moneim A, Aleck K, et al. Further delineation of Kabuki syndrome in 48 well-defined new individuals. Am J Med Genet A. 2005;132A(3):265‐272. - PubMed

LinkOut - more resources